Indian Journal of Medical and Paediatric Oncology

LinksSchließen

Referenz

Solomon BJ, Bauer TM, Felip E. et al.
Safety and efficacy of lorlatinib (PF-06463922) from the dose escalation component of a study in patients with advanced ALK+ or ROS1+ non-small cell lung cancer (NSCLC).

J Clin Oncol 2016;
34 (Suppl. 01) 9009-9009

Bibliographische Angaben herunterladen

Aufrufen in: